Device Trial Radar · NCT05227053
STOP AF First Post-Approval Study
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
142
Actual
Start
Apr 28, 2022
Primary completion
Sep 18, 2026
Study completion Sep 18, 2026
Sponsor
- Lead sponsor
- Medtronic Cardiac Ablation SolutionsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Feb 7, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Conditions
- Paroxysmal Atrial Fibrillation
Interventions
Arctic Front™ Cardiac Cryoablation CatheterDevice
Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)Time frame: 36 months
- Freedom from Primary Safety EventsTime frame: 12 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Alaska Heart Institute
Anchorage, Alaska
Cardiology Associates of Fairfield County
Stamford, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.